



Newstar Medical Laboratories - Atlanta

975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144

Phone: (678) 505-8016 | Fax:(678) 806-7192

CLIA ID: 11D2145553

Laboratory Director : Chesie Voma

PAI	IEN	

DEMOGRAPHICS

Patient Name: MARY JONES

DOB: 12/22/1951

Patient Gender: F

Patient Phone Number: (520) 868-4812

Account: Desert Kidney Associates Casa Grande Florence

Provider: Ruchir Patel

Accession: 21120600024

Report Status:

Re

PRESCRIPTION

LIST

Losartan (Cozaar) , Amlodipine (Norvasc) , Furosemide (Lasix) , Atorvastatin (Lipitor) , Oxycodone (OXY , Percocet , Endocet , Percodan , Percolone , Roxicodone , Tylox) , Vitamin D3 (cholecalciferol-D3) (D3-50) , Triamcinolone (Aristocort) , Zolpidem (Ambien)

C20, Z51.81, Z79.899, I10 Hypertension, N18.2

		INCONSISTENT	
OT PRESCRIBE Class	Test	Cutoff ^(ng/mL)	DET Results ^(ng/mL)
STIMULANT	Caffeine	50	> 2500
	[DDI] The metabolism	n of Zolpidem can be decreased when	combined with Caffeine.

		INCONSISTENT
PRESCRIBED		NOT DETECTED
Class	Test	Cutoff ^(ng/mL)
STATIN	Atorvastatin	10
STATIN	[DDI] The metabolism or severity of hypokal metabolism of Zolpid myopathy, rhabdomy with Atorvastatin. The Triamcinolone. [DDI] The metabolism or severity of hypokal metabolism of Zolpid myopathy, rhabdomy with Atorvastatin. The Triamcinolone. [DDI] The metabolism or severity of hypokal metabolism of Zolpid myopathy, rhabdomy with Atorvastatin. The Triamcinolone. [DDI] The metabolism or severity of hypokal metabolism of Zolpid myopathy, rhabdomy with Atorvastatin. The Triamcinolone. [DDI] The metabolism or severity of hypokal metabolism of Zolpid myopathy, rhabdomy with Atorvastatin. The Triamcinolone. [DDI] The metabolism or severity of hypokal metabolism of Zolpid myopathy rhabdomy with Atorvastatin. The Triamcinolone. [DDI] The metabolism or severity of hypokal metabolism of Zolpid	n of Atorvastatin can be decreased when combined with Losartan. In of Atorvastatin can be decreased when combined with Losartan. In of Atorvastatin can be decreased when combined with Losartan. In of Atorvastatin can be decreased when combined with Losartan. In of Atorvastatin can be decreased when combined with Losartan. In of Atorvastatin can be decreased when combined with Losartan. In of Atorvastatin can be decreased when combined with Losartan. In of Atorvastatin can be decreased when combined with Losartan. In of Oxycodone can be increased when combined with Triamcinolone. The risk lemia can be increased when Triamcinolone is combined with Furosemide. The tem can be increased when combined with Triamcinolone. The risk or severity of volysis, and myoglobinuria can be increased when Triamcinolone. The risk or severity of volysis, and myoglobinuria can be increased when combined with Triamcinolone. The risk lemia can be increased when Triamcinolone is combined with Furosemide. The lem can be increased when combined with Triamcinolone. The risk or severity of volysis, and myoglobinuria can be increased when Triamcinolone. The risk or severity of volysis, and myoglobinuria can be increased when combined with Triamcinolone. The risk lemia can be increased when combined with Triamcinolone. The risk or soverity of volysis, and myoglobinuria can be increased when Triamcinolone. The risk or severity of volysis, and myoglobinuria can be increased when Triamcinolone. The risk or severity of volysis, and myoglobinuria can be increased when Triamcinolone is combined with Triamcinolone. The risk or severity of volysis, and myoglobinuria can be increased when Triamcinolone is combined with Furosemide. The lem can be increased when Triamcinolone is combined with Triamcinolone. The risk or severity of volysis, and myoglobinuria can be increased when Triamcinolone. The risk or severity of volysis, and myoglobinuria can be increased when Combined with Triamcinolone. The risk lemia can be increased when Triamcinolone is combi
	Triamcinolone.	e metabolism of Amlodipine can be increased when combined with
	or severity of hypokal metabolism of Zolpid myopathy, rhabdomy	n of Oxycodone can be increased when combined with Triamcinolone. The risk lemia can be increased when Triamcinolone is combined with Furosemide. The lem can be increased when combined with Triamcinolone. The risk or severity of rolysis, and myoglobinuria can be increased when Triamcinolone is combined e metabolism of Amlodipine can be increased when combined with

[DDI] The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when

Triamcinolone is combined with Atorvastatin.

CONTRAINDICATION	NOT TESTED
Drug	Contraindication
Furosemide	[CI] Contraindicated withChronic kidney disease, stage 2 (mild) [CI]Chronic kidney disease, stage 2 (mild) [CI] Chronic kidney disease, stage 2 (mild) [CI] Chronic kidney disease, stage 2 (mild) [DDI] The risk or severity of renal failure and hypotension can be increased when Furosemide is combined with Losartan.
Triamcinolone	[DDI] The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Furosemide. [DDI] The metabolism of Zolpidem can be increased when combined with Triamcinolone.
Zolpidem	[DDI] Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The metabolism of Zolpidem can be decreased when combined with Losartan. [DDI] Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The metabolism of Zolpidem can be decreased when combined with Losartan. [DDI] Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The metabolism of Zolpidem can be decreased when combined with Losartan. [DDI] Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The metabolism of Zolpidem can be decreased when combined with Losartan. [DDI] Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The metabolism of Zolpidem. Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The metabolism of Zolpidem. Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The metabolism of Zolpidem. The metabolism of Zolpidem can be decreased when combined with Losartan. [DDI] The metabolism of Zolpidem can be decreased when combined with Losartan.

	CONSISTENT				VALIDITY TESTING & SCRE	ENS	Newstar Newstar		
回校国 🔻					Specimen Validity	Range	Results N	MEDICAL LABORATORIES Newstar Medical Laboratories - Atlanta	
Trong Address NGC 1985	Task	Cutoff ^(ng/mL)	R CareView	7 360		-	975 Cobb Place B	Blvd NW, STE 218 Kennesaw, GA 30144	
	Test	Cuton	KI COLL COLL		— '	4.50 - 8.00		e: (678) 505-8016 Fax:(678) 806-7192	
.R	Amlodipine	25	87.01		Specific Gravity	1.01 - 1.03	1.009	CLIA ID: 11D2145553	
		the hypotensive activities of Furo			Urine Creatinine ^(mg/dL)	20.00 - 400.00	27.14	Laboratory Director : Chesie Vorha	
ATIENT		the hypotensive activities of Furos i he hmaky រូប់សុខទ ះtivities of Furos		Accour	it: Desert Kidney Associates Casa Grande I	Florence	Order Code: 2021-0011992		
EMOGRAPHICS	[DDI] Amlodipine may increase t	the hypotensive activities of Furos	semide.	Provid	er Ruchir Patel		Sample Type: Urine		
	[DDI] Amiodipine may increase t	the hypotensive activities of Furos	semide.	Access	ion: 21120600024		Collected: 12/02/2021		
		the hypotensive activities of Euros one Number: (520) 868-4812			Status:		Received: 2021-12-06T15:34:17.18105	50	
		done can be increased when com be increased when Triamcinolone					Reported: 04/05/2022		
	metabolism of Zolpidem can be	increased when combined with T	riamcinolone. The risk or sever	rity of					
		I myoglobinuria can be increased sm of Amlodipine can be increase		ed					
	Triamcinolone.	·							
		done can be increased when com be increased when Triamcinolone							
	metabolism of Zolpidem can be	increased when combined with T	riamcinolone. The risk or sever	rity of					
		I myoglobinuria can be increased sm of Amlodipine can be increase		ed					
	Triamcinolone.								
		done can be increased when com be increased when Triamcinolone							
		increased when combined with T							
		I myoglobinuria can be increased sm of Amlodipine can be increase		ed					
	Triamcinolone.	sirror Armodipine earroe increase	a when combined with						
	•	done can be increased when com be increased when Triamcinolone							
		increased when combined with T							
		I myoglobinuria can be increased		ed					
	Triamcinolone.	sm of Amlodipine can be increase	a when combined with						
	•	done can be increased when com							
		be increased when Triamcinolone increased when combined with T							
		d myoglobinuria can be increased		ed					
	With Atorvastatin. The metabolis Triamcinolone.	sm of Amlodipine can be increase	d when combined with						
		done can be increased when com							
		be increased when Triamcinolone increased when combined with T							
		I myoglobinuria can be increased		ed					
	with Atorvastatin. The metabolis Triamcinolone.	sm of Amlodipine can be increase	d when combined with						
	[DDI] The metabolism of Amlodi	ipine can be increased when com	bined with Triamcinolone.						
OPIOID	Oxycodone	50	61.73						
	[DDI] The metabolism of Atorvas	statin can be decreased when cor	mbined with Oxycodone. The ri	sk or					
		ne increased when Oxycodone is of statin can be decreased when cor							
		pe increased when Oxycodone is o							
		statin can be decreased when cor be increased when Oxycodone is o							
		statin can be decreased when cor							
		ne increased when Oxycodone is of statin can be decreased when cor							
		be increased when Oxycodone is o							
		statin can be decreased when cor be increased when Oxycodone is o							
		statin can be decreased when cor							
	[DDI] The risk or severity of adve Oxymorphone.	erse effects can be increased whe	n Oxycodone is combined with	1					
		f Furosemide can be decreased w	hen used in combination with						
	Oxycodone. [DDI] The therapeutic efficacy of	f Furosemide can be decreased w	then used in combination with						
		rity of renal failure and hypotensi							
	Furosemide is combined with Lower when used in combination with	osartan. The therapeutic efficacy of Oxycodone.	of Furosemide can be decrease	d					
		f Furosemide can be decreased w	hen used in combination with						
		rity of renal failure and hypotensions artan. The therapeutic efficacy of		d					
	when used in combination with		or rai oscimac carroc accrease	u					
		f Furosemide can be decreased writy of renal failure and hypotension							
		osartan. The therapeutic efficacy		d					
	when used in combination with	Oxycodone. f Furosemide can be decreased w	then used in combination with						
		rity of renal failure and hypotensi							
	Furosemide is combined with Lower when used in combination with	osartan. The therapeutic efficacy of	of Furosemide can be decrease	d					
		f Furosemide can be decreased w	hen used in combination with						
		rity of renal failure and hypotensi		d					
	when used in combination with	osartan. The therapeutic efficacy of Oxycodone.	or rui oseimue cam de decrease	u					
		f Furosemide can be decreased writy of renal failure and hypotensi							
		osartan. The therapeutic efficacy of		d					
	when used in combination with		hinad with Take and the Take	riol:					
	•	done can be increased when com be increased when Triamcinolone							
	vewstahwarrantszehatdamatanhan	ysisr provided is rconducted profes	sionally phace of danies with the	á <mark>þ</mark> ρΩξable	e standard laboratory practices and that this				
·	10 to		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		have not been cleared or approved by the Fo	_	·	· · · · · · · · · · · · · · · · · · ·	
	Triamcinolone. Omer and relying on the establishe	ed government databases availab	le to Newstar for the specific s	ample(s).	Newstar disclaims any and all liability for any				
	•	done can be increased when com be increased when Triamcinolone							
		increased when combined with T							

Patient Name: MARY JONES Patient Name: MARY JONES
[DDI] The metabolism of Oxycodone can be increased when combined with Triamcinolone. The risk

Lab: Newstar Medical Laboratories of Daylor Released when Triamcinolone is combined with Furosemid Page 2 / 3

Triamcinolone.

myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined

with Atorvastatin. The metabolism of Amlodipine can be increased when combined with

Accession: 2112060 024 Generated: 04/05/2022





Newstar Medical Laboratories - Atlanta
975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144
Phone: (678) 505-8016 | Fax:(678) 806-7192
CLIA ID: 11D2145553

Laboratory Director : Chesie Voma

PATIENT

DEMOGRAPHICS

Patient Name: MARY JONES	Account: Desert Kidney Associates Casa Grande Florence	Order Code: 2021-0011992
DOB: 12/22/1951	Provider: Ruchir Patel	Sample Type: Urine
Patient Gender: F	Accession: 21120600024	Collected: 12/02/2021
Patient Phone Number: (520) 868-4812	Report Status:	Received: 2021-12-06T15:34:17.181050
		Reported: 04/05/2022

NOT PRESCRIBED							NOT DETECTED
Test	Cutoff ^(ng/mL)	Test	Cutoff ^(ng/mL)	Test	Cutoff ^(ng/mL)	Test	Cutoff ^(ng/mL)
Quetiapine	50	alpha-Hydroxyalprazolam	30	Dihydrocodeine	50	Norbuprenorphine	30
Ritalinic Acid		Alprazolam	30	Diltiazem	50	Nordiazepam	40
Sertraline	50	Amitriptyline	50	Ethyl Sulfate		Norfentanyl	8
Tapentadol	50	Amphetamine	200	Glipizide	10	Norhydrocodone	50
Temazepam	40	Aripiprazole	20	Glyburide	10	Norhydromorphone	
Topiramate	50	Atenolol	50	Haloperidol	25	Normeperidine	100
Pitavastatin	10	Atomoxetine	50	Hydrocodone	50	Norpropoxyphene	100
Pregabalin	150	Baclofen	50	Hydromorphone	50	Nortriptyline	50
Propoxyphene		Buprenorphine	10	Hydroxybupropion	50	Norverapamil	50
Propranolol	50	Bupropion		Ibuprofen		Protriptyline	50
Paroxetine	25	Buspirone	50	Imipramine	50	Pseudoephedrine	50
Phentermine	100	Carbamazepine	50	Indomethacin	50	Risperidone	10
Pioglitazone	50	Carbamazepine Epoxide		Irbesartan	50	Rivaroxaban	50
Diphenhydramine	50	Carboxyclopidogrel	50	Levetiracetam	50	Rosuvastatin	20
Donepezil	50	Carisoprodol	100	Lisinopril	50	Salicylic Acid	400
Doxepin	30	Celecoxib	50	Lorazepam	40	Sitagliptin	50
Duloxetine	50	Chlorpromazine	25	Lurasidone	25	Sumatriptan	50
Ethyl Glucuronide		Citalopram		Meperidine		THC-COOH	50
Fentanyl	2	Clonazepam	20	Meprobamate	200	Tramadol	100
Fluoxetine	25	Clonidine	50	Metformin	500	Trazodone	50
Gabapentin	1000	Clopidogrel		Methylphenidate		Valsartan	50
O-Desmethyltramadol	100	Clozapine		Metoprolol	50	Venlafaxine	100
O-Desmethylvenlafaxine	100	Codeine	50	Mirtazapine		Verapamil	
Olanzapine	25	Cotinine	50	Morphine	50	Warfarin	10
Oxazepam	40	Cyclobenzaprine	50	Naloxone	10	Ziprasidone	25
Hydrochlorothiazide	50	Dehydroaripiprazole	20	Naproxen	100	Zolmitriptan	50
4-Hydroxydiclofenac	50	Desipramine	50	N-Desmethylcitalopram	50		
7-Aminoclonazepam	40	Diazepam	10	N-Desmethylclozapine	25		
9-Hydroxyrisperidone	10	Diclofenac	50	N-Desmethylmirtazapine	25		
Acetaminophen	400	Digoxin	10	N-Desmethylolanzapine	25		

IMPORTANT DISCLAIMER NOTICE: Newstar warrants that all lab analysis provided is conducted professionally in accordance with all applicable standard laboratory practices and that this data reflects Newstar's attempt to generate accurate results for the specific sample(s) submitted to generate this report. Newstar has developed the tests used during the lab analysis and determined their performance characteristics. The tests have not been cleared or approved by the Food and Drug Administration. The results provided are based on information provided by the Customer. Report results are contingent on the accuracy of the prescription list, diagnosis codes, and government databases used to determine drug contraindications and drug interactions. This data reflects Newstar's attempt to generate accurate results based on the information that was provided to Newstar by the Customer and relying on the established government databases available to Newstar for the specific sample(s). Newstar disclaims any and all liability for any errors and is not responsible for any claims or damages related to the reliability of the test results.